(Reuters) Authorities in Peru and Morocco have approved Phase 3 clinical trials for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said late on Thursday on Chinese social media platform WeChat.
Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has entered a Phase 3 trial in the United Arab Emirates that has already recruited 15,000 volunteers.
It has also obtained approval to be tested in Bahrain in a Phase 3 study designed to involve around 6,000 participants.
Source: Reuters; Reporting by Roxanne Liu and Tony Munroe in Beijing; Editing Shri Navaratnam and Stephen Coates